Synergy Biomedical has announced that it has recently received US Food and Drug Administration (FDA) clearance and will be launching its first bone graft product, BioSphere putty. Utilising a specialised form of 45S5 bioactive glass with a unique sphere shape and a narrow size range, BioSphere putty, according to a company release, provides an optimised bone graft material that outperforms other bioactive products.
The company reported that the spherical shape of the BioSphere particles provides uniform and repeatable resorption and ion release. In addition, the thee-dimensional packing of the spheres in a bone defect creates an optimal porosity that allows bone formation throughout the implant. Biosphere putty is composed of bioactive glass spheres that are combined with a mouldable phospholipid carrier. The putty, according to the release, has the highest bioactive glass composition on the market, provides excellent handling, and is resistant to irrigation. This combination results in a high performance bone graft that provides faster and more robust bone formation.
“We are excited to introduce a next generation bone graft product to the orthopaedic community that represents advancement in bone grafting technology”
“The use of spherical particles has allowed Synergy to identify an optimal form of bioactive glass that improves bone formation,” stated Mark Borden, CEO and founder of Synergy Biomedical. “We are excited to introduce a next generation bone graft product to the orthopaedic community that represents advancement in bone grafting technology,” stated.
